Ikena Oncology Inc Stock

$14.15

0.56%

Nasdaq, Mon, Aug 25 2025

ISIN

US45175G1085

Symbol

IKNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Ikena Oncology Inc Stock price

$14.15

-1.85 11.56% 5Y

Nasdaq, Closing price Mon, Aug 25 2025

-0.08 0.56%

ISIN

US45175G1085

Symbol

IKNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

Enterprise Value

Net debt

positive

Cash

$114.1m

Shares outstanding

48.3m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

89.0%

Return on Equity

-39.1%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $0.0

EBITDA

- | $-90.8m

EBIT

- | $-11.1m

Net Income

- | $-10.3m

Free Cash Flow

$-38.3m

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

Ikena Oncology Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Ikena Oncology Inc forecast:

6x Buy

75%

2x Hold

25%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Ikena Oncology Inc forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Ikena Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	24 24	5% 5% -
- Research and Development Expense	31 31	48% 48% -
EBITDA	-54 -54	27% 27% -
- Depreciation and Amortization	0.49 0.49	52% 52% -
EBIT (Operating Income) EBIT	-55 -55	28% 28% -
Net Profit	-49 -49	28% 28% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Ikena Oncology Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

Neutral

GlobeNewsWire

●

about one month ago

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company will operate un...

Neutral

GlobeNewsWire

●

about one month ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio (“Imagene”), of the combined company after the anticipated closing.

More Ikena Oncology Inc News

Company Profile

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Head office	United States
CEO	Mark Manfredi
Employees	9
Founded	2016
Website	www.ikenaoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now